Johnson & Johnson anticipates 14 new multibillion-dollar drugs by 2025
Category: #headlines  | By Nikita Chaurasia  | Date: 2021-11-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Johnson & Johnson anticipates 14 new multibillion-dollar drugs by 2025
  • Johnson & Johnson to focus on pharma division after the split into drug and consumer companies.
  • The company is working on 14 new drugs, all of which have a market potential of USD 1 billion each.  

American multinational corporation Johnson & Johnson (J&J) expects to petition for approval of 14 novel blockbuster drugs, each with potential for at least USD 1 billion in sales by 2025, execs stated during a strategy review of the company.

The move comes after the company announced its intention to spin off its consumer health business, which sells Listerine and Band-Aid bandages, to focus on pharmaceuticals and medical equipment. J&J is following the footsteps of several other pharmaceutical companies that have downscaled to focus on their pharmaceutical divisions.

Mathai Mammen, global head of research, J&J Janssen pharmaceutical division, mentioned that the company is developing an anticoagulant with partner Bristol Myers Squibb for non-small cell lung cancer, and a respiratory syncytial virus (RSV) vaccine.

He described them as the top pipeline assets the company has. Mammen also stated that he does not believe the deal will have a significant impact on R&D investment.

It is worth noting that J&J produced one of the three COVID-19 vaccines approved in the United States, however, its use in the country dropped drastically after its possible connection with rare incidences of blood clotting.

Nonetheless, J&J intends to produce more vaccines using the same viral vector technology, expressed Mammen.

The conglomerate was actively looking at various technological platforms, including messenger RNA, which is the backbone of Moderna and Pfizer's COVID-19 vaccines, and partner BioNTech's as well, he added.

Knowledgeable sources cited that Johnson & Johnson expects to be a USD 60 billion-a-year pharmaceutical company by 2025. The firm aims to generate revenue at a compound annual rate of at least 5% per year through mid-decade.

The company will depend on a combination of established medicines, innovative treatments, and novel, breakthrough therapeutics like CAR-T drugs and gene therapies to achieve the set goals.

Source Credits- 

https://money.usnews.com/investing/news/articles/2021-11-18/j-j-sees-potential-for-14-new-multibillion-dollar-drugs-by-2025

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...